Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases by Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang

“…Abstract Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. …”
Get full text

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS by Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“…The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.   …”
Get full text

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

Application of Bionanomaterials in Tumor Immune Microenvironment Therapy by Jiawei Wang, Yan Bao, Yandan Yao

“…Immune checkpoint blockade therapy and chimeric antigen receptor T-cell (CAR-T) immunotherapy are clinically effective in a variety of cancers. …”
Get full text

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy? by Sonja S. Mojsilovic, Slavko Mojsilovic, Victor H. Villar, Juan F. Santibanez

“…Also, new macrophage-based cell therapeutic technologies recently developed using chimeric antigen receptor bioengineering are exposed, which may overcome all solid tumor physical barriers impeding the current adoptive cell therapies and contribute to developing novel cancer immunotherapies.…”
Get full text

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES by Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone

“… Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. …”
Get full text

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity by Congcong Zhang, Anja Waldmann, Winfried S Wels, Jasmin Röder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Nina Müller, Pranav Oberoi

“…Furthermore, NKAB-ErbB2 synergized with NK-92 cells or primary T cells engineered to express an NKG2D-CD3ζ chimeric antigen receptor (NKAR), leading to targeted cell killing and greatly enhanced antitumor activity, which remained unaffected by soluble MICA known as an inhibitor of NKG2D-mediated natural cytotoxicity. …”
Get full text

The success of the tumor immunotherapy: neutrophils from bench to beside by Meng Zhu, Ru Jia, Xiaojie Zhang, Pingwei Xu

“…The present immune therapy was focused on the immune checkpoint blockade or Chimeric Antigen Receptor T-Cell Immunotherapy (CART) transfer, but how to activate the innate immune system to antitumor still lags out. …”
Get full text

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases by Yuehong Chen, Jianhong Sun, Huan Liu, Geng Yin, Qibing Xie

“…Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. …”
Get full text

Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma by Min Meng, Yi-chen Wu

“…Background. Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. …”
Get full text

Toll-Like Receptor-Based Strategies for Cancer Immunotherapy by Saghar Pahlavanneshan, Ali Sayadmanesh, Hamidreza Ebrahimiyan, Mohsen Basiri

“…These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. …”
Get full text

CAR-T cell therapy in developing countries: how long should we wait? by Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C

“…However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.The Center for Regenerative Medicine in Nepal has initiated efforts to make CAR-T cell therapy accessible to patients with cancer at a substantially reduced cost. …”
Get full text

Innovative immunotherapies and emerging treatments in type 1 diabetes management by Malek Zarei, Mohammad Abbas Sheikholeslami, Masoud Mozaffari, Yassar Mortada

“…Novel approaches, such as Chimeric Antigen Receptor (CAR)–Tregs therapy and JAK-STAT pathway inhibition, represent exciting areas of ongoing research. …”
Get full text

Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review by Kiran Shah, Nirali Shah, Fatameh Ghassemi, Carolyn Ly, Teena George, Carla Lutz, Huseyin Sumer

“…The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA’s Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. …”
Get full text

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma by Saffron E. Summers, Saffron E. Summers, Vehid Salih, Andrew D. Foey

“…Chimeric antigen receptor T (CAR-T) cell therapy has shown great success in treating B cell malignancies; however, there are many challenges that limit their therapeutic efficacy in solid tumours. …”
Get full text

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma by Gustavo de Oliveira Canedo, Claire Roddie, Persis J. Amrolia

“…Abstract: Relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy remains a major challenge in B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). …”
Get full text

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma by Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng

“…The chimeric antigen receptor-modified immune effector cell (CAR-T and CAR-NK) therapies are newly developed adoptive treatments of cancers. …”
Get full text

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma? by Davor Galusic, Ivan Krecak, Viktor Blaslov, Andela Krstulovic Opara, Toni Valkovic, Sandra Basic Kinda

“…Due to the cost and availability of bispecific T cell redirecting antibodies (BsAbs) and chimeric antigen receptor T cell therapy (CAR-T) in real-life settings in many countries, retreatment with daratumumab in subsequent lines of therapy might be a reasonable choice. …”
Get full text

Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer by Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An

“…Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. …”
Get full text

Upregulation of CD19 by low‐dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma by Ying Ni, Qun Zhang, Xiaochen Tang, Xiuchun Li, Shiguang Ye, Yan Lu, Aibin Liang, Ping Li

“…In recent years, CD19 Chimeric antigen receptor T (CAR T) cell immunotherapy has significantly improved the cure rate of B-NHL patients, but there are still some patients who cannot achieve remission after treatment, or relapse after remission. …”
Get full text